Case researcher in RNA biology makes waves by challenging current thinking

With her collaborator, Ambro van Hoof, Ph.D. of The University of Texas Health Sciences Center, Baker directly tested the “faux 3’ UTR” model and proved it could not explain how cells recognize and destroy deviant mRNA. This landmark discovery will redirect mRNA research and expand opportunities for new discoveries in understanding the cells’ ability to protect itself from these potential errors.

In all cells, including human, mRNA is a copy of the information carried by a gene on the DNA. Occasionally, mRNA contains errors that can make the information it carries unusable. Cells posses a remarkable mechanism to detect these aberrant mRNAs and eliminate them from the cell – this process represents a very important quality control system for gene expression. “A significant amount of past research in this area of RNA biology has collected data to support the ‘faux 3’ UTR’ model for mRNA quality control, and, as a result, has shaped present research directions in the field,” said Baker. “Our recent findings preclude this explanation and will, undoubtedly, result in a rethinking by many as to how to experimentally approach this important cellular process.”

For decades researchers have been puzzled by cells’ ability to differentiate between “normal” mRNA and those carrying certain types of mutations. mRNA transports DNA’s genetic coding information to the sites of protein synthesis: ribosomes. Cells are able to identify mRNA carrying a mutation and prevent it from reaching the protein synthesis phase. Once identified, the cell destroys the abnormal, mutated mRNA. This naturally occurring process ensures malfunctioning proteins are not produced. Using a yeast model system, Baker’s research offers a better understanding of this mRNA quality control process which closely mimics the process in human cells.

Baker’s research on nonsense-mediated mRNA decay not only provides an advanced understanding of an important process in the regulation of gene expression, but may help lead to new therapeutic strategies in the treatment of genetic diseases. Many inherited conditions, including cystic fibrosis, are a consequence of mutations resulting in the recognition of non-functional mRNA and the subsequent elimination by nonsense-mediated mRNA decay. Because cells eliminate the abnormal mRNA, no protein is produced.

With genetic diseases, researchers are hypothesizing it might be beneficial for the cell to express the protein, even though it is not completely functional. The rational is it will be better for these patients to have protein of some function rather than no protein at all. Cystic fibrosis clinical trials are currently underway with a goal of producing the partially functional proteins, before the cell’s natural elimination process takes place. Using Baker’s findings, researchers will have a better understanding of how to modulate the recognition of the abnormal mRNAs as to allow the mRNA to remain in the cell and produce the protein.

“This finding is an important step in advancing our understanding of mRNA function,” said Baker. “In addition, it emphasizes the important link between basic and clinical science; the more we understand the basic biological processes that are underway in the cell, the better equipped we are to directly address clinical therapies.”

Source: Case Western Reserve University

As rates rise, researchers find better way to identify melanoma
University of Rochester Medical Center researchers found a new protein produced excessively in malignant melanoma, a discovery that is particularly relevant as skin cancer rates climb dramatically among young women.
Location, location, location
Neuroscientists at Georgetown University Medical Center have solved a mystery that lies at the heart of human learning, and they say the solution may help explain some forms of mental retardation as well as provide clues to overall brain functioning.
Combining medical knowledge to save lives
European researchers hope to gain more insight into cardiovascular disease by combining clinical, laboratory and metabolic records with genomic data.
Cardiovascular disease (CVD) is the biggest killer among chronic diseases, claiming 17 million lives globally every year. Yet doctors can only attribute 50% of cardiovascular diseases to known risk factors.
Researchers show antibody to breast cancer-secreted protein blocks metastasis
Scientists at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia have made a key discovery about the mechanism of breast cancer metastasis, the process by which cancer spreads. Focusing on a gene dubbed "Dachshund," or DACH1, they are beginning to pinpoint new therapeutic targets to halt the spread of cancer.
Gene variation may be why some don't respond to cholesterol-lowering drugs
A variation in the way the body processes a single protein may explain why some people don't respond well to drugs that lower "bad" cholesterol, according to a report in Circulation: Journal of the American Heart Association.
Need microRNA processing? Get Smad
Researchers at Tufts University School of Medicine and Tufts Medical Center have found that Smad proteins regulate microRNA (miRNA) processing. Understanding the role of Smad proteins enables researchers to investigate abnormal miRNA processing which is a contributing factor in development of cardiovascular disorders and cancer. The study was published online today in Nature.
Mechanism may explain aspects of brain impairment seen in Fragile X Syndrome
Scientists report that a protein associated with a common form of mental retardation plays an important role in intracellular trafficking within neurons. The research, published by Cell Press in the June issue of the journal Developmental Cell, reveals new information about how neuronal communication and plasticity are affected in Fragile X Syndrome (FXS).
How cell's master transcribing machine achieves near perfection
One of the most critical processes in biology is the transcription of genetic information from DNA to messenger RNA (mRNA), which provides the blueprint for the proteins that form the machinery of life. Now, researchers have discovered new details of how the cell's major transcriptional machinery, RNA polymerase II (Pol II), functions with such exquisite precision. With almost unerring accuracy, Pol II can select the correct molecular puzzle piece, called a nucleosidetriphosphate (NTP), to add to the growing mRNA chain, although these puzzle pieces can be highly similar molecules.

Case researcher in RNA biology makes waves by challenging current thinking

Related stories:

News discussion: